Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab or ravulizumab in paroxysmal nocturnal hemoglobinuria under routine clinical practice
2019-001453-10Phase 4Terminated
- Sponsor
- Roche
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of eculizumab and ravulizumab in paroxysmal nocturnal hemoglobinuria (PNH) (2 cohorts), sponsored by Roche. Primary endpoint: LDH levels over time with eculizumab. Started Aug 2019; status: terminated.
02
Drugs
eculizumabravulizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2019-001453-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001453-10.